Downloads: 92

Files in This Item:
File Description SizeFormat 
s12886-018-0914-z.pdf851.66 kBAdobe PDFView/Open
Title: Long-term efficacy and safety of anti-VEGF therapy in retinitis pigmentosa: a case report
Authors: Miyata, Manabu  kyouindb  KAKEN_id  orcid (unconfirmed)
Oishi, Akio
Oishi, Maho
Hasegawa, Tomoko
Ohashi Ikeda, Hanako
Tsujikawa, Akitaka  kyouindb  KAKEN_id
Author's alias: 宮田, 学
大石, 明生
大石, 真秀
長谷川, 智子
池田, 華子
辻川, 明孝
Keywords: Retinitis pigmentosa
Anti-VEGF therapy
Choroidal neovascularization
Issue Date: 14-Sep-2018
Publisher: BMC
Journal title: BMC ophthalmology
Volume: 18
Thesis number: 248
Abstract: [Background]Retinitis pigmentosa (RP), a neurodegenerative disease, is occasionally accompanied by choroidal neovascularization (CNV) and cystoid macular oedema. It is presently treated with repeated intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents. However, there are concerns regarding long-term inhibition of VEGF by the use of these agents, especially in cases involving neurodegenerative diseases, since VEGFs have a neuroprotective effect. Currently, there are no reports on the long-term safety of anti-VEGF therapy in patients with RP. [Case presentation]In this report, we describe the case of a 56-year-old female patient with CNV associated with RP who was treated with anti-VEGF therapy for 8 years. She had autosomal dominant RP with a heterozygous PRPH2 mutation (c.410G > A) and complained of metamorphopsia in her left eye. Examinations revealed CNV with serous retinal detachment. She was treated with as-needed injections for 2 years; however, she experienced a recurrence. Therefore, we switched to a bimonthly regimen that was continued for 6 years. In total, the patient received 34 injections of various types of anti-VEGFs over 8 years. No recurrences were noted during that time, and we have not detected any negative effects concerning the progression of visual field loss in comparison with the fellow eye. [Conclusions]No negative effects related to the progression of visual field loss were observed during continuous treatment with anti-VEGF agents for 8 years in our patient.
Rights: © The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.
DOI(Published Version): 10.1186/s12886-018-0914-z
PubMed ID: 30217183
Appears in Collections:Journal Articles

Show full item record

Export to RefWorks

Export Format: 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.